A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer

The mammalian target of rapamycin (mTOR) plays a critical role in promoting tumor cell growth and is frequently activated in breast cancer. In preclinical studies, the antitumor activity of mTOR inhibitors is attenuated by feedback up-regulation of AKT mediated in part by Insulin-like growth factor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res Treat
Main Authors: Ma, Cynthia X., Suman, Vera J., Goetz, Matthew, Haluska, Paul, Moynihan, Timothy, Nanda, Rita, Olopade, Olufunmilayo, Pluard, Timothy, Guo, Zhanfang, Chen, Helen X., Erlichman, Charles, Ellis, Matthew J., Fleming, Gini F.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517667/
https://ncbi.nlm.nih.gov/pubmed/23605083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2528-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados